IP Library Granted Patent US 12,453,595
Granted Patent B2
US 12,453,595 · App. 18/416,522 · Granted Oct 28, 2025

Systems and methods for delivering modulated radiofrequency power to treat tissue

Inventors: William Lucas Churchill (Bolton, MA); Danielle Gline Allen (Derry, NH)
Assignee: Hologic, Inc.
A61B18/1233A61B2018/00267A61B2018/00559A61B2018/00577A61B2018/00642A61B2018/00702A61B2018/0072A61B2018/00875A61B2018/126A61B2018/1475
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,453,595
App. No.
18/416,522
Granted
Oct 28, 2025
Kind
B2
Abstract

A system for modulating delivery of radiofrequency (RF) power to tissue, the system including an RF applicator configured for being positioned adjacent to tissue, an RF generator electrically coupled to the RF applicator, and a controller operatively coupled to the RF generator. The controller includes a tissue impedance measurement circuit operatively coupled with the RF applicator and configured for measuring an impedance of tissue disposed adjacent to the RF applicator, and a power modulation module configured to cause RF power to be delivered from the RF generator to the tissue disposed adjacent to the RF applicator so that an impedance of the tissue tracks a target tissue impedance as a function of time.

Claims (45)

1. A system for modulating delivery of radiofrequency (RF) power to tissue, comprising:

an RF applicator configured for being positioned adjacent to tissue;

an RF generator electrically coupled to the RF applicator; and

a controller operatively coupled to the RF generator, wherein the controller comprises

a tissue impedance measurement circuit operatively coupled with the RF applicator and configured for measuring an impedance of tissue disposed adjacent to the RF applicator, and

a power modulation module configured to cause RF power to be delivered from the RF generator to the tissue disposed adjacent to the RF applicator so that an impedance of the tissue tracks a target tissue impedance as a function of time, wherein the target tissue impedance as a function of time is determined by scaling a preexisting tissue impedance curve based upon a measured initial impedance of the tissue.

2. The system of claim 1 , wherein the RF applicator comprises an electrode carrier including one or more bipolar electrode pairs thereon.

3. The system of claim 1 , wherein the preexisting tissue impedance curve is derived from impedance data obtained from prior performed tissue ablation procedures.

4. The system of claim 1 , wherein a target tissue impedance, It, for a given time t following an initial time period during a tissue ablation procedure is determined according to a formula,

It=I max−(( I max Io )* S ),

where

Imax is a target maximum impedance of the tissue,

Io is a projected impedance of the tissue for the given time t during the procedure derived from a function approximating the preexisting tissue impedance curve, and

S is a scaling factor equal to (Imax−Imeas)/(Imax−Iio), where Imeas is the measured initial impedance of the tissue, and Iio is a projected initial impedance of the tissue derived from the function approximating the preexisting tissue impedance curve.

5. The system of claim 4 , wherein the procedure is an endometrial lining tissue ablation procedure, the duration of the endometrial lining ablation procedure is about 120 seconds, Imax is about 50 ohms, and the function approximating the preexisting endometrial lining tissue ablation impedance curve is

It= 4+(49( T/ 120)),

where T is a given time (in seconds) during the endometrial lining ablation procedure.

6. The system of claim 1 , wherein the controller is configured to cause the RF power to be delivered to the tissue until (i) the impedance of the tissue reaches a target maximum tissue impedance, or (ii) a duration of the delivery of RF power reaches a target completion time, whichever occurs first.

7. The system of claim 1 , wherein the controller is configured to modulate the delivery of the RF power to the tissue by causing one of increasing, decreasing, or maintaining constant a delivered RF current to the tissue at regular power adjustment intervals.

8. The system of claim 7 , wherein, at each power adjustment interval, an amperage of the delivered RF current is not increased or decreased more than a predetermined adjustment limit.

9. The system of claim 8 , wherein the predetermined adjustment limit is about 3%.

10. A method of delivering RF power to tissue, comprising:

delivering radiofrequency (RF) power to tissue via an applicator positioned adjacent to the tissue; and

modulating the delivery of RF power so that impedance of the tissue tracks a predetermined target tissue impedance as a function of time, wherein the target tissue impedance as a function of time is determined by scaling a preexisting tissue impedance curve based upon a measured initial impedance of the tissue.

11. The method of claim 10 , wherein the preexisting tissue impedance curve is derived from impedance data obtained from prior performed tissue ablation procedures.

12. The method of claim 11 , wherein a target tissue impedance, It, for a given time t following an initial time period during a tissue ablation procedure is determined according to a formula,

It=I max−(( I max− Io )* S ),

where

Imax is a target maximum tissue impedance,

Io is a projected tissue impedance for the given time t derived from a function approximating the preexisting tissue impedance curve, and

S is a scaling factor equal to (Imax−Imeas)/(Imax−Iio), where Imeas is a measured initial impedance of the tissue at an expiration of the initial time period, and Iio is a projected impedance of the tissue derived from the function approximating the preexisting tissue impedance curve.

13. The method of claim 12 , wherein the RF power is delivered during an endometrial lining tissue ablation procedure, wherein the target maximum tissue impedance is about 50 ohms, and wherein the function approximating the preexisting tissue ablation impedance curve is

IT= 4+(49( T/ 120)),

where IT is a target tissue impedance (in ohms) for a given time T (in seconds) during the ablation period procedure.

14. The method of claim 10 , wherein the RF power is delivered to the tissue until (i) the impedance of the tissue reaches a target maximum tissue impedance, or (ii) a target ablation procedure completion time is reached, whichever occurs first.

15. The method of claim 10 , wherein modulating the delivery of RF power to the tissue comprises one of increasing, decreasing, or maintaining constant a delivered RF current at regular power adjustment intervals.

16. The method of claim 15 , wherein, at each power adjustment interval, the amperage of the delivered RF current is not increased or decreased more than a predetermined adjustment limit.

17. A system for delivering RF power to tissue, comprising:

a radiofrequency (RF) generator; and

a controller operatively coupled with the RF generator, wherein the controller is configured to

(a) cause the generator to deliver RF power to tissue electrically coupled to the generator,

(b) determine a target tissue impedance as a function of time by scaling a preexisting tissue impedance curve based upon a measured initial impedance of the tissue, and

(c) modulate the delivery of RF power so that a measured impedance of the tissue tracks the target tissue impedance as a function of time.

18. The system of claim 17 , wherein the controller is configured to cause the RF power to be delivered to the tissue until (i) the impedance of the tissue reaches a target maximum tissue impedance, or (ii) a target procedure completion time is reached, whichever occurs first.

19. The system of claim 17 , wherein the RF power is delivered during an endometrial lining tissue ablation procedure, the system further comprising an RF energy applicator configured for being positioned in a uterine cavity for delivering the RF power from the generator to endometrial lining tissue within the uterine cavity, the applicator comprising an electrode carrier including one or more bipolar electrode pairs thereon.

Assignments (4)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 069172/0436 Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC.; GEN-PROBE INCORPORATED; FAXITRON BIOPTICS, LLC
Reel/Frame 075503/0086 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 14, 2024
From: HOLOGIC, INC.; GEN-PROBE INCORPORATED; FAXITRON BIOPTICS, LLC
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 069172/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2024
From: CHURCHILL, WILLIAM LUCAS; ALLEN, DANIELLE GLINE
To: HOLOGIC, INC.
Reel/Frame 066183/0556 →
Continuity (6)
Continuation 18093480 · Jan 5, 2023
Continuation 16998836 · Aug 20, 2020
Continuation 16001366 · Jun 6, 2018
Continuation 14574070 · Dec 17, 2014
Provisional Application 61920152 · Dec 23, 2013
Related Publication 20240156510A1 · May 16, 2024
References Cited (33)
US 4474179A · Koch · 1984 [cited by applicant]
US 5769880A · Truckai et al. · 1998 [cited by applicant]
US 5817093A · Williamson, IV et al. · 1998 [cited by applicant]
US 5954717A · Behl et al. · 1999 [cited by applicant]
US 6033399A · Gines · 2000 [cited by applicant]
US 6080149A · Huang et al. · 2000 [cited by applicant]
US 6508815B1 · Strul et al. · 2003 [cited by applicant]
US 6843789B2 · Goble · 2005 [cited by applicant]
US 8080008B2 · Wham et al. · 2011 [cited by applicant]
US 8152801B2 · Goldberg et al. · 2012 [cited by applicant]
US 8241275B2 · Hong et al. · 2012 [cited by applicant]
US 8357151B2 · Goldberg et al. · 2013 [cited by applicant]
US 8486060B2 · Kotmel et al. · 2013 [cited by applicant]
US 9333034B2 · Hancock · 2016 [cited by applicant]
US 10004553B2 · Churchill · 2018 [cited by examiner]
US 10779877B2 · Churchill · 2020 [cited by examiner]
US 11559348B2 · Churchill · 2023 [cited by examiner]
US 11918276B2 · Churchill · 2024 [cited by examiner]
US 20050203504A1 · Wham et al. · 2005 [cited by applicant]
US 20070173804A1 · Wham · 2007 [cited by examiner]
US 20070282320A1 · Buysse et al. · 2007 [cited by applicant]
US 20080071257A1 · Kotmel · 2008 [cited by examiner]
US 20080228181A1 · Godara et al. · 2008 [cited by applicant]
US 20090234351A1 · Desinger et al. · 2009 [cited by applicant]
US 20100324548A1 · Godara et al. · 2010 [cited by applicant]
US 20110144635A1 · Harper et al. · 2011 [cited by applicant]
US 20120136354A1 · Rupp · 2012 [cited by applicant]
US 20130304060A1 · Truckai · 2013 [cited by examiner]
US 20150224326A1 · Toth · 2015 [cited by examiner]
Notice of Allowance for U.S. Appl. No. 16/998,836 dated Sep. 28, 2022. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/001,366 dated Mar. 19, 2020. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/001,366 dated May 21, 2020. [cited by applicant]
PCT International Search Report and Written Opinion for International Application No. PCT/US2014/070959, Applicant Hologic, Inc., forms PCT/ISA/210, 220, and 237, dated Mar. 24, 2015 (16 pages). [cited by applicant]